Form 4: Lyell Immunopharma Director Acquires 200,000 Shares in Open Market Purchase

Director Sumant Ramachandra purchased 200,000 shares of Lyell Immunopharma at an average price of $0.5761 on March 21, 2025.

Summary

• On March 21, 2025, Sumant Ramachandra, a director of Lyell Immunopharma, acquired 200,000 shares of common stock.
• The shares were purchased at a weighted average price of $0.5761, with individual prices ranging from $0.5487 to $0.5879.
• The transaction increased Ramachandra's indirect beneficial ownership through the Sumant Ramachandra Rev Trust DTD 01/24/12.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the purchase itself is a positive signal, the document is simply a regulatory filing reporting the transaction.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's prospects. A director's purchase, as in this case, is often viewed more favorably than a sale.

Stakeholder Impact

• The stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Lyell Immunopharma, insider trading, Sumant Ramachandra, stock purchase, Form 4, beneficial ownership, director